RXRX: Recursion Pharmaceuticals, Inc. Stock

by  •  • Comments Off on RXRX: Recursion Pharmaceuticals, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 1,843.29
Enterprise Value ($M) 1,452.87
Book Value ($M) 463.44
Book Value / Share 1.97
Price / Book 3.98
NCAV ($M) 247.87
NCAV / Share 1.05
Price / NCAV 7.44

Profitability (mra)
Return on Invested Capital (ROIC) -0.64
Return on Assets (ROA) -0.52
Return on Equity (ROE) -0.76

Liquidity (mrq)
Quick Ratio 4.70
Current Ratio 4.70

Balance Sheet (mrq) ($M)
Current Assets 438.14
Assets 653.70
Liabilities 190.26
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 44.58
Operating Income -350.06
Net Income -328.07

Cash Flow Statement (mra) ($M)
Cash From Operations -287.78
Cash from Investing -10.23
Cash from Financing 140.13

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Vanguard Group Inc 7.52 55.76
02-12 13G/A ARK Investment Management LLC 11.08 11.73
02-09 13G Fmr Llc 5.23
01-29 13G/A BlackRock Inc. 6.00 16.18
01-26 13G/A Baillie Gifford & Co 11.61 -2.58
01-24 13G State Street Corp 5.83
05-22 13G Kinnevik AB (publ) 5.60

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PUR
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION R
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT
2023-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPOR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 888,465 3,701,678 24.00
2024-04-25 756,724 3,785,513 19.99
2024-04-24 1,367,321 1,974,266 69.26
2024-04-23 592,138 1,213,198 48.81
2024-04-22 621,833 1,118,176 55.61

(click for more detail)

Similar Companies
RPRX – Royalty Pharma plc RPTX – Repare Therapeutics Inc.
RVMD – Revolution Medicines, Inc. SANA – Sana Biotechnology, Inc.
SCPH – scPharmaceuticals Inc.


Financial data and stock pages provided by
Fintel.io